Reduction of prohibitin expression contributes to left ventricular hypertrophy via enhancement of mitochondrial reactive oxygen species formation in spontaneous hypertensive rats

Free Radical Research

Volumn 49, Issue 2, 2015, Pages 164-174

  Zheng, H ^a   Lu, G M ^b  

^a DONGHUA UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Left ventricular hypertrophy; Mitochondria; Prohibitin; Reactive oxygen species; Spontaneously hypertensive rats

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; LOSARTAN; MALONALDEHYDE; PROHIBITIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; TEMPOL; UBIQUINOL CYTOCHROME C REDUCTASE; REPRESSOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MITOCHONDRION SWELLING; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; WEIGHT HEIGHT RATIO; WESTERN BLOTTING; WISTAR KYOTO RAT; ANIMAL; BIOSYNTHESIS; BLOOD; COMPLICATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEART MITOCHONDRION; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM;

RATTUS;

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ANIMALS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, HEART; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; VENTRICULAR FUNCTION;

EID: 84926680761     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2014.991724     Document Type: Article

References (55)

1. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 2003;93:1179-1192.
2. Kass DA, Bronzwaer J G, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004;94:1533-1542.
3. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 2002;90:1055-1063.
4. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003;92:139-150.
5. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004;322:1178-1191.
6. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW II, et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res 2000;86:255-263.
7. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 2006;103:7432-7437.
8. Paolisso G, Galzerano D, Gambardella A, Varricchio G, Saccomanno F, D'Amore A, et al. Left ventricular hypertrophy is associated with a stronger impairment of non-oxidative glucose metabolism in hypertensive patients. Eur J Clin Invest 1995;25:529-533.
9. Li L, Yi-Ming W, Li ZZ, Zhao L, Yu YS, Li DJ, et al. Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats. Pharmacol Res 2008;58:196-201.
10. Matsui H, Shimosawa T, Uetake Y, Wang H, Ogura S, Kaneko T, et al. Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension 2006;48:225-231.
11. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schoneich C, Cohen RA. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004;10:1200-1207.
12. Zhang X, Klein AL, Alberle NS, Norby FL, Ren BH, Duan J, Ren J. Cardiac-specific overexpression of catalase rescues ventricular myocytes from ethanol-induced cardiac contractile defect. J Mol Cell Cardiol 2003;35:645-652.
13. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98:794-799.
14. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002;105:509-515.
15. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J, et al. Reactive oxygen species mediate amplitudedependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001;89:453-460.
16. Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 2001; 289:901-907.
17. Ago T, Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal 2007;9: 679-687.
18. Kuster GM, Siwik DA, Pimentel DR, Colucci WS. Role of reversible, thioredoxin-sensitive oxidative protein modifications in cardiac myocytes. Antioxid Redox Signal 2006;8:2153-2159.
19. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidasedependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006;71:208-215.
20. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-388.
21. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003;35:851-859.
22. McLachlan J, Beattie E, Murphy MP, Koh-Tan CH, Olson E, Beattie W, et al. Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens 2014;32:555-564.
23. Dai DF, Chen T, Szeto H, Nieves-Cintrón M, Kutyavin V, Santana LF, Rabinovitch PS. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 2011;58:73-82.
24. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cochemé HM, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009;54:322-328.
25. Gregory-Bass RC, Olatinwo M, Xu W. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer 2008;122:1923-1930.
26. Ikonen E, Fiedler K, Parton RG, Simons K. Prohibitin, an antiproliferative protein, is localized to mitochondria. FEBS Lett 1995 358:273-277.
27. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Löwer B, Wunderlich FT, et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev 2008;22:476-488.
28. Kasashima K, Sumitani M, Satoh M, Endo H. Human prohibitin 1 maintains the organization and stability of the mitochondrial nucleoids. Exp Cell Res 2008;314:988-996.
29. Schleicher M, Shepherd BR, Suarez Y, Fernandez-Hernando C, Yu J, Pan Y, et al. Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J Cell Biol 2008;180:101-112.
30. Liu X, Ren Z, Zhan R, Wang X, Wang X, Zhang Z, et al. Prohibitin protects against oxidative stress-induced cell injury in cultured neonatal cardiomyocyte. Cell Stress Chaperones 2009;14:311-319.
31. Zhou P, Qian L, D'Aurelio M, Cho S, Wang G, Manfredi G, et al. Prohibitin reduces mitochondrial free radical production and protects brain cells from different injury modalities. J Neurosci 2012;32:583-592.
32. Kathiria AS, Butcher LD, Feagins LA, Souza RF, Boland CR, Theiss AL. Prohibitin 1 modulates mitochondrial stressrelated autophagy in human colonic epithelial cells. PLoS One 2012;7:e31231.
33. Zhou TB, Qin YH, Lei FY, Huang WF, Drummen GP. Prohibitin is associated with antioxidative protection in hypoxia/reoxygenation-induced renal tubular epithelial cell injury. Sci Rep 2013;3:3123.
34. Zhou TB, Qin YH, Lei FY, Huang WF, Drummen GP. Prohibitin attenuates oxidative stress and extracellular matrix accumulation in renal interstitial fibrosis disease. PLoS One 2013;8:e77187.
35. Kim N, Lee Y, Kim H, Joo H, Youm JB, Park WS, et al. Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics. Proteomics 2006;6:1237-1249.
36. Chowdhury D, Tangutur AD, Khatua TN, Saxena P, Banerjee SK, Bhadra MP. A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. J Transl Med 2013;11:130.
37. Sun B, Wang JH, Lv YY, Zhu SS, Yang J, Ma JZ. Proteomic adaptation to chronic high intensity swimming training in the rat heart. Comp Biochem Physiol Part D Genomics Proteomics 2008;3:108-117.
38. Lord KC, Shenouda SK, McIlwain E, Charalampidis D, Lucchesi PA, Varner KJ. Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction. Cardiovasc Res 2010;87:111-118.
39. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003;21:1961-1967.
40. Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J. TNF-α-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. Am J Physiol Heart Circ Physiol 2007; 293:H2726-H2737.
41. Schlüter KD, Piper HM. Isolation and culture of adult ventricular cardiomyocytes. In: Dhein S, Mohr F, Delmar M (eds.). Practical methods in cardiovascular research. Berlin: Springer; 2005. Pp. 557-567.
42. Boveris A, Cadenas E, Stoppani AOM. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem J 1976;156:435-444.
43. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973;134:707-716.
44. Jüllig M, Hickey AJ, Chai CC, Skea GL, Middleditch MJ, Costa S, et al. Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics 2008;8:2556-2572.
45. Wikman-Coffelt J, Parmley WW, Mason DT. The cardiac hypertrophy process. Analyses of factors determining pathological vs. physiological development. Circ Res 1979;45: 697-707.
46. Muders F, Elsner D. Animal models of chronic heart failure. Pharmacol Res 2000;41:605-612.
47. McClung JK, Jupe ER, Liu XT, Dell'Orco RT. Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 1995;30:99-124.
48. Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW, et al. Prohibitins act as a membrane bound chaperone for the stabilization of mitochondrial proteins. EMBO J 2000;19:2444-2451.
49. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780-787.
50. Bourges I, Ramus C, Mousson de Camaret B, Beugnot R, Remacle C, Cardol P, et al. Structural organization of mitochondrial human complex I: role of the ND4 and ND5 mitochondria-encoded subunits and interaction with prohibitin. Biochem J 2004;383: 491-499.
51. Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 1999;31:949-970.
52. Baker KM, Booz GW, Dostal DE. Cardiac action of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992;54: 227-241.
53. Zhang YH, Dingle L, Hall R, Casadei B. The role of nitric oxide and reactive oxygen species in the positive inotropic response to mechanical stretch in the mammalian myocardium. Biochim Biophys Acta 2009;1787: 811-817.
54. De Giusti VC, Caldiz CI, Ennis IL, Pérez NG, Cingolani HE, Aiello EA. Mitochondrial reactive oxygen species (ROS) as signaling molecules of intracellular pathways triggered by the cardiac renin-angiotensin II-aldosterone system (RAAS). Front Physiol 2013;4:126.
55. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001;276:39721-39726.